Evidence map›Paper›PMID 40161087›Full record

ArticleCureus2025

Endobronchial Valves for Recurrent Hemoptysis Secondary to Aspergilloma: A Case Report and Literature Review.

Parnia Khamooshi, Karthik Vijayan, Michael DiRico, Hiren Mehta

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Parnia KhamooshiPulmonary and Critical Care Medicine, University of Florida, Gainesville, USA.
Karthik VijayanPulmonary and Critical Care Medicine, University of Florida, Gainesville, USA.
Michael DiRicoPulmonary and Critical Care Medicine, University of Florida, Gainesville, USA.
Hiren MehtaPulmonary and Critical Care Medicine, University of Florida, Gainesville, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aspergilloma is a common cause of hemoptysis and can result in significant morbidity and mortality in patients with structural lung disease. While surgical resection is the gold standard for treating aspergilloma, many patients are not suitable candidates for surgery. In this report, we explore the use of endobronchial valves (EBVs) as a non-surgical alternative for managing recurrent hemoptysis in a patient with interstitial lung disease (ILD) and a left upper lobe aspergilloma. Despite previous treatments, including antifungals and radiation, the patient experienced persistent hemoptysis and was not a candidate for either bronchial artery embolization or lobectomy. An EBV was implanted in the affected lung segment, resulting in the resolution of the hemoptysis without valve-related complications on the six-month follow-up. While the use of EBVs for hemoptysis management has been reported in a few cases, this is, to our knowledge, the first report in a patient with ILD. This approach presents a viable non-surgical alternative in complex cases where conventional treatments have proven ineffective or are not feasible.

Indexed as

aspergillomachronic pulmonary aspergillosisendobronchial valveshemoptysisinterstitial lung disease

Identifiers

PMID40161087
PMCPMC11951946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.